MOL0 Stock Chart & Stats
€6.45
--
Market closed
€6.45
--
Day’s Range― - ―
52-Week Range€6.45 - €6.60
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€10.68M
Enterprise Value€4.95M
Total Cash (Recent Filing)€10.32M
Total Debt (Recent Filing)€326.00K
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Aug 19, 2026EPS Estimate
-1.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-27.98
Shares Outstanding5,336,350
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.26
Price to Sales (P/S)0.00
P/FCF Ratio-0.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€14.01Price Target Upside117.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pivotal Trial EfficacyRobust early efficacy signals in the pivotal Phase 2/3 MIRACLE trial demonstrate Annamycin’s potential to meaningfully improve remission rates versus standard cytarabine in relapsed/refractory AML. If durable, this can underpin regulatory approval, broaden clinical adoption and create sustainable commercial opportunity in a high-unmet-need oncology niche.
Favorable Cardiac SafetyA consistent, independently reviewed absence of cardiotoxicity versus traditional anthracyclines is a durable clinical differentiator. This safety profile can expand patient eligibility, reduce monitoring burdens, ease regulatory labeling constraints, and increase the drug’s competitive advantage across hematologic and solid tumor indications.
Strengthened IP ProtectionExtending patent coverage to 2040 in key Asian jurisdictions adds a lasting exclusivity layer to Annamycin. Strong, geographically broad IP supports long-term commercialization planning, licensing negotiations and value capture across major markets, reinforcing the company’s strategic moat if clinical success is achieved.
Bears Say
No Product RevenueAs a clinical-stage company with no marketed products, Moleculin lacks recurring product revenue; persistent multi-year net losses reflect an extended development timeline. This structural absence of commercial cash flow makes long-term viability contingent on successful trials, partnerships or recurring financing events.
High Cash BurnSustained negative operating and free cash flow at material levels implies ongoing depletion of financial resources to fund R&D and trials. High structural burn limits strategic flexibility, shortens runway absent financing or milestones, and elevates execution risk for multi-year clinical programs.
Reliance On Dilutive FinancingFrequent equity/warrant issuance and recent exercises (generating modest proceeds) show reliance on dilutive capital to fund operations. This structural financing model increases shareholder dilution risk, may constrain institutional support, and can divert management focus toward capital raises over program execution.
Moleculin Biotech News
MOL0 FAQ
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest stock price was €6.45 and its highest was €6.60 in the past 12 months.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market cap is €10.68M.
When is Moleculin Biotech’s upcoming earnings report date?
Moleculin Biotech’s upcoming earnings report date is Aug 19, 2026 which is in 36 days.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on May 15, 2026. The company reported -€3.108 earnings per share for the quarter, missing the consensus estimate of -€2.048 by -€1.06.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate is -1.41.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 5,336,350 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of -€3.108 in its last earnings report, missing expectations of -€2.048. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in DE:MOL0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Moleculin Biotech
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
MOL0 Stock 12 Month Forecast
Average Price Target
€14.01
▲(117.25% Upside)
Options Prices
Currently, No data available
---